CSIMarket
 
Transmedics Group Inc   (TMDX)
Other Ticker:  
 
 
Price: $75.9400 $-2.88 -3.654%
Day's High: $77.85 Week Perf: -7.42 %
Day's Low: $ 74.81 30 Day Perf: -15.08 %
Volume (M): 917 52 Wk High: $ 99.63
Volume (M$): $ 69,614 52 Wk Avg: $72.78
Open: $77.40 52 Wk Low: $36.48



 Market Capitalization (Millions $) 2,477
 Shares Outstanding (Millions) 33
 Employees 194
 Revenues (TTM) (Millions $) 192
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) 223
 Capital Exp. (TTM) (Millions $) 113

Transmedics Group Inc
TransMedics Group Inc. (NASDAQ: TMDX) is a medical technology company headquartered in Andover, Massachusetts that is dedicated to improving organ transplant outcomes. The company was founded in 1998 and has since developed innovative solutions to maintain organ viability during transportation, known as the Organ Care System (OCS).

The OCS is a portable platform that enables organ transplants by providing uninterrupted blood flow, oxygenation, and preservation of organs during transportation. The OCS is compatible with a variety of organ types, including hearts, lungs, and livers, and has been shown to increase the number of organs suitable for transplantation and improve transplant outcomes.

TransMedics is focused on increasing patient access to transplants by improving organ preservation and reducing the risk of transplant-related complications. The company is dedicated to delivering innovative tools and services that can significantly increase the number of organs available for transplantation.

The company has a global presence, with a presence in Europe, the United States, and Asia. TransMedics has commercialized the OCS in over 30 countries and has obtained regulatory approval for its products from major regulatory authorities, including the United States, Europe, Canada, and Australia.

TransMedics has also received numerous awards and accolades for its innovative technology, including being named a finalist in the 2021 Edison Best New Product Awards for its OCS LUNG platform.

TransMedics is positioned for continued growth, with a strong pipeline of ongoing clinical trials and a dedicated team of experts working to develop new solutions that are transforming the field of organ transplant medicine. The company is committed to bringing its innovative technologies to organ transplant patients around the world, providing hope and new opportunities for those in need of life-saving transplants.


   Company Address: 200 Minuteman Road Andover 1810 MA
   Company Phone Number: 552-0900   Stock Exchange / Ticker: NASDAQ TMDX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Transmedics Group Inc

TMDX Struggles to Achieve Profitability Despite Remarkable Revenue Surge

Transmedics Group Inc, a leading player in the Medical Equipment & Supplies sector, has recently announced robust financial results for the third quarter of 2023. Their revenue recorded an impressive growth of 158.654% year on year, amounting to $66.43 million during the July to September period. However, shareholders were disheartened by the increased shortfall per share, reaching $-0.78.
In comparison to its peers in the Medical Equipment & Supplies sector, Transmedics Group Inc experienced a considerably higher growth rate in top-line revenue. The average top-line growth for the two third businesses in this sector was merely 4.49% relative to the same period last year. This indicates that Transmedics Group Inc is outperforming its competitors in terms of revenue expansion.

Transmedics Group Inc

Transmedics Group Inc Shatters Expectations with Stupendous 155% Growth in Q2 of 2023!

Exciting Growth and Promising Future for Transmedics Group Inc in the Stock Market
Transmedics Group Inc, a leading medical device company, has recently announced its financial results for the second quarter of 2023, and the numbers are truly impressive. Investors have every reason to be excited about the stock market potential of this innovative company.
One of the most remarkable achievements for Transmedics Group Inc is the significant reduction in loss per share compared to the previous year. In Q2 2023, the company decreased its loss per share to $-0.03, a substantial improvement from $-0.41 a year ago. This indicates a tremendous shift towards profitability and demonstrates the company's ability to navigate challenges and chart a course for success.

Transmedics Group Inc

Transmedics Group Inc Makes Stunning Turnaround, Erasing Deficit in Recent Fiscal Period

The stock market is a volatile space, and investors should approach it with caution. While financials can give an indication of a company's performance, there are several other factors to consider before investing in a stock. In this context, the recent performance of Transmedics Group Inc sparks some interest.
The company recently reported revenue growth of 161.675% to $41.55 million in the most recent fiscal period, compared to $15.88 million in the same reporting period a year ago. Sequentially, revenue surged by 32.443% from $31.38 million. This is an encouraging sign for investors, as it indicates a promising growth trend.






 

Transmedics Group Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com